Colinz Laboratories (BOM:531210) E10: ₹1.10 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531210 Colinz Laboratories Ltd BOM:531210
65 GF Score
Price ₹80.13
GF Value ₹42.35
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Colinz Laboratories E10?

Colinz Laboratories BOM:531210 -2.28% 65 E10 is ₹1.10 as of Dec. 2025. GuruFocus rates BOM:531210 with a GF Score™ of 65/100 and a GF Value™ of ₹42.35 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Colinz Laboratories's adjusted earnings per share data for the three months ended in Dec. 2025 was ₹0.330. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹1.10 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Colinz Laboratories's average E10 Growth Rate was 20.90% per year. During the past 3 years, the average E10 Growth Rate was 30.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Colinz Laboratories was 30.70% per year. The lowest was 29.40% per year. And the median was 30.05% per year.

As of today (2026-07-23), Colinz Laboratories's current stock price is ₹80.13. Colinz Laboratories's E10 for the quarter that ended in Dec. 2025 was ₹1.10. Colinz Laboratories's Shiller PE Ratio of today is 72.85.

During the past 13 years, the highest Shiller PE Ratio of Colinz Laboratories was 116.50. The lowest was 21.11. And the median was 57.38.


Colinz Laboratories  (BOM:531210) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Colinz Laboratories's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=80.13/1.10
=72.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Colinz Laboratories was 116.50. The lowest was 21.11. And the median was 57.38.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Colinz Laboratories E10 Related Terms


Colinz Laboratories E10 Historical Data

* Premium members only.

The historical data trend for Colinz Laboratories's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Colinz Laboratories E10 Chart

Colinz Laboratories Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.43 0.61 0.78 0.96

Colinz Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.96 1.01 1.07 1.10

BOM:531210 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Colinz Laboratories's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Colinz Laboratories Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Colinz Laboratories's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Colinz Laboratories's Shiller PE Ratio falls into.


BOM:531210
65GF Score
Colinz Laboratories Ltd BOM:531210
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Colinz Laboratories E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Colinz Laboratories's adjusted earnings per share data for the three months ended in Dec. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.33/163.2808*163.2808
=0.330

Current CPI (Dec. 2025) = 163.2808.

Colinz Laboratories Quarterly Data

per share eps CPI Adj_EPS
201603 0.034 102.518 0.054
201606 0.070 105.961 0.108
201609 0.170 105.961 0.262
201612 0.040 105.196 0.062
201703 0.040 105.196 0.062
201706 -0.023 107.109 -0.035
201709 0.105 109.021 0.157
201712 0.128 109.404 0.191
201803 0.120 109.786 0.178
201806 0.077 111.317 0.113
201809 0.120 115.142 0.170
201812 0.043 115.142 0.061
201903 0.026 118.202 0.036
201906 0.114 120.880 0.154
201909 0.094 123.175 0.125
201912 0.101 126.235 0.131
202003 -0.024 124.705 -0.031
202006 0.119 127.000 0.153
202009 0.220 130.118 0.276
202012 0.065 130.889 0.081
202103 0.135 131.771 0.167
202106 0.180 134.084 0.219
202109 0.340 135.847 0.409
202112 0.190 138.161 0.225
202203 0.150 138.822 0.176
202206 0.440 142.347 0.505
202209 0.460 144.661 0.519
202212 0.410 145.763 0.459
202303 0.510 146.865 0.567
202306 0.480 150.280 0.522
202309 0.490 151.492 0.528
202312 0.420 152.924 0.448
202403 0.540 153.035 0.576
202406 0.540 155.789 0.566
202409 0.620 157.882 0.641
202412 0.210 158.323 0.217
202503 0.600 157.552 0.622
202506 0.470 159.755 0.480
202509 0.560 162.289 0.563
202512 0.330 163.281 0.330

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹1.10 mean?
Colinz Laboratories (BOM:531210) has a E10 of ₹1.10 as of Dec. 2025. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Colinz Laboratories and its competitors.
Is Colinz Laboratories' E10 too high?
Colinz Laboratories' current E10 is ₹1.10. Overall, Colinz Laboratories has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Colinz Laboratories' E10 compare to ZTS and UTHR?
Colinz Laboratories' E10 of ₹1.10 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Colinz Laboratories and its competitors. Colinz Laboratories's current E10 is ₹1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Colinz Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Colinz Laboratories (BOM:531210) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹42.35, compared to a current price of ₹80.13 — trading 89.2% above its estimated fair value. The current E10 is ₹1.10. Colinz Laboratories' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Colinz Laboratories (BOM:531210), the current E10 is ₹1.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Colinz Laboratories (BOM:531210) Overvalued in 2026?

Based on GuruFocus' analysis, Colinz Laboratories stock appears to be overvalued. The current stock price of ₹80.13 is trading 89.2% above its estimated GF Value™ of ₹42.35. GuruFocus considers Colinz Laboratories to be Significantly Overvalued.

Key valuation signals for BOM:531210:

  • E10: ₹1.10
  • GF Value™: ₹42.35 vs. price of ₹80.13 (89.2% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the BOM:531210 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Colinz Laboratories Business Description

Address Mulund Goregaon Link Road, A-101 Pratik Industrial Estate, Next to Fortis Hospital, Bhandup (West), Mumbai, MH, IND, 400078
Colinz Laboratories Ltd is an India-based company engaged in manufacturing and trading in Pharmaceutical formulations. It offers formulations in the products category of ayurvedic, allopathic, and nutraceuticals. The company manufactures pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, and others. It also has certain specialized products for gynecology, cardiology, gastroenterology, and others. The group derives revenue from the sale of its products in India.
65GF Score

Get the complete analysis for BOM:531210

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹80.13
Price
₹42.35
GF Value